Akeso's Ivonescimab achieves positive overall survival results against Pembrolizumab in first-line NSCLC treatment
Executive summary: Akeso, Inc. announced positive overall survival (OS) results from its Phase III HARMONi-2 study, which compared Ivonescimab to Pembrolizumab for first-line treatment of PD-L1-positive NSCLC. The results suggest Ivonescimab could displace current market-leading immunotherapies in a major oncology indication, impacting the competitive landscape of lung cancer treatment.
Who is involved: Akeso, Inc. (developer), patients with PD-L1-positive NSCLC, and major pharmaceutical competitors.
Likely next: Regulatory filings for market approval in key jurisdictions based on the registrational trial data.
Akeso, Inc. presented Phase III HARMONi-2 trial data at the WCLC 2026 conference, demonstrating that Ivonescimab provides a statistically significant survival advantage in patients with PD-L1-positive non-small cell lung cancer (NSCLC). This result directly challenges the current market dominance of Pembrolizumab in the first-line setting. The successful outcome positions Ivonescimab as a potential new standard-of-care for this specific patient population.
What's next — scenarios
Base: Regulatory approval and market entry (65%)
Akeso secures approvals, leading to rapid adoption in the NSCLC first-line market.
- Successful FDA/NMPA/EMA submissions
- Confirmation of safety profile in regulatory reviews
Upside: Expansion into combination therapies (25%)
Ivonescimab is used alongside other agents (e.g., chemotherapy or TKIs) to expand its market share.
- Positive data from combination studies
- Partnerships with major global pharma
Downside: Safety concerns or regulatory delays (10%)
Unforeseen adverse events or insufficient data lead to restricted labeling or delayed approval.
- New safety signals in post-market surveillance
- Regulatory requests for additional subgroup analyses
What to watch
- Official regulatory filing timelines from Akeso (late 2026/2027)
- Comparative market share data in the NSCLC immunotherapy segment
- Upcoming oncology conference updates regarding Ivonescimab safety data
Timeline
- — Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026 (PR Newswire)
- — RYBREVANT FASPRO™ plus LAZCLUZE® shows low rates of treatment-related events at WCLC 2026 (PR Newswire)
- — Zipalertinib Plus Chemotherapy Significantly Extends PFS in First-Line EGFR Exon 20 Insertion-Positive NSCLC (PR Newswire)
- — Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves PFS in HER2-Mutant NSCLC (PR Newswire)
Analysis — what this means
Likely next events
- Regulatory submission process for HARMONi-2 results (post-WCLC 2026)
Sectors affected
- Biopharmaceuticals
- Oncology therapeutics
- Healthcare capital markets
Regulatory implications
- Submission of registrational data to global health authorities for first-line NSCLC indication
Historical parallels
- Pembrolizumab (Keytruda) establishing dominance in first-line NSCLC (circa 2016)
Key entities
Sources
- Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026 — PR Newswire
- RYBREVANT FASPRO™ plus LAZCLUZE® shows low rates of treatment-related events at WCLC 2026 — PR Newswire
- Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves PFS in HER2-Mutant NSCLC — PR Newswire
- Zipalertinib Plus Chemotherapy Significantly Extends PFS in First-Line EGFR Exon 20 Insertion-Positive NSCLC — PR Newswire
Related cases
- Johnson & Johnson's subcutaneous regimen for NSCLC shows strong safety profile at WCLC 2026
- PTK7 emerges as stable ADC target in EGFR wild-type NSCLC, boosting Whitehawk's HWK-007 prospects
- Sacituzumab govitecan plus pembrolizumab fails to meet primary endpoints in first‑line PD‑L1‑high metastatic NSCLC, dealing a setback to the ADC‑immunotherapy combo approach
- Akeso's Ivonescimab demonstrates superior overall survival compared to Pembrolizumab in PD-L1-positive NSCLC
- SystImmune’s Phase 1 data for Iza-bren show promising activity in EGFR‑mutated lung cancer, backing a 2.5 mg/kg dose for Phase 3
- Akeso initiates Phase II trial of a novel TROP2/Nectin-4 bispecific ADC combined with Ivonescimab, advancing its oncology pipeline in NSCLC